• Contents
• Letter of transmittal
• User guide
• part 1: overview of the nba and the blood sector
• part 2: highlights of 2011–12
• NBA's Performance
  (PARTS 3,4, AND 5)
• part 3: performance: securing the supply of blood and blood products
• part 4: performance: improving the sector and its management of risk
• part 5: performance: supporting appropriate and safe use of blood and blood products
• part 6: Corporate management
• part 7: financial management and accountability
• part 8: appendices
  • A1 Blood sector stakeholders and governance
  • A2 The National Blood Agreement: objectives of governments
  • A3 NBA agency resource statement
  • A4 NBA Board Members
  • A5 Fresh blood components supplied under contract by the blood service 2011–12
  • A6 Plasma and recombinant products supplied under contract in 2011–12
  • A7 Units of red cells, platelets and IVIg issued per 1000 head of population by state and territory 2007–08 to 2011–12
  • A8 Responsibility and composition of governance committees
  • A9 Mandatory reporting
  • A10 Errata
  • A11 Glossary of terms and acronyms
  • A12 List of requirements

appendicies

APPENDIX 2.THE NATIONAL BLOOD AGREEMENT: OBJECTIVES OF GOVERNMENTS

1. The primary policy objectives for the Australian blood sector are:
   1. to provide an adequate, safe, secure and affordable supply of blood products, blood related products and blood related services in Australia
   2. to promote safe, high quality management and use of blood products, blood related products and blood related services in Australia.
2. In pursuing the primary policy objectives, the Parties will have regard to the following secondary policy aims:
   1. to meet international obligations and standards
   2. to maintain reliance on voluntary, non-remunerated donations of whole blood and plasma
   3. to promote national self-sufficiency
   4. to provide products to patients, free of charge and based on clinical need and appropriate clinical practice
   5. to promote optimal safety and quality in the supply, management and use of products, including through uniform national standards
   6. to make best use of available resources, and to give financial and performance accountability for the use of resources by all entities involved in the Australian blood sectors
   7. to undertake national information gathering, monitoring of new developments, reporting and research in relation to the Australian blood sector
   8. to maintain flexibility and capacity to respond in a timely manner to changing circumstances and needs
   9. to ensure public support and confidence in the Australian blood sector
   10. to work towards optimal access to blood and blood products across the nation, ensuring that patients continue to access the blood products and blood related products their clinicians determine will best meet their needs so far as practicable in accordance with national best practice based on clinical guidelines. This clause does not preclude states and territories from altering the range of blood products and blood related products that are prescribed and received in their jurisdiction.